Genevive | |
3433 Broadway St Ne Suite 300 Minneapolis MN 55413-1761 | |
(763) 587-7737 | |
(763) 587-7781 |
Full Name | Genevive |
---|---|
Speciality | Family Medicine |
Location | 3433 Broadway St Ne, Minneapolis, Minnesota |
Authorized Official Name and Position | Amanda Simpson Tufano (CEO) |
Authorized Official Contact | 7635877737 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Genevive 3433 Broadway St Ne Suite 300 Minneapolis MN 55413-1761 Ph: (763) 587-7737 | Genevive 3433 Broadway St Ne Suite 300 Minneapolis MN 55413-1761 Ph: (763) 587-7737 |
NPI Number | 1093131419 |
---|---|
Provider Enumeration Date | 03/10/2014 |
Last Update Date | 04/16/2020 |
Medicare PECOS PAC ID | 2365667557 |
---|---|
Medicare Enrollment ID | O20140701002173 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1093131419 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207QG0300X | Family Medicine - Geriatric Medicine | (* (Not Available)) | Primary |
Provider Name | Tara L Schlattman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609853415 PECOS PAC ID: 5193621522 Enrollment ID: I20031208000916 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Krista J Naber |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1699752535 PECOS PAC ID: 4486553732 Enrollment ID: I20040107000066 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Brian J Dixon |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1528096161 PECOS PAC ID: 5294635488 Enrollment ID: I20040113000262 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Nancy A Schultz |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346278579 PECOS PAC ID: 6406740950 Enrollment ID: I20040214000075 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | John W Mielke |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1679508006 PECOS PAC ID: 0042104598 Enrollment ID: I20040214000080 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Alan S Divine |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1104825280 PECOS PAC ID: 9032004734 Enrollment ID: I20040220000593 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Sarah Louise Isakson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1730128505 PECOS PAC ID: 2365420957 Enrollment ID: I20040709001269 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Amy L Foster |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1811963382 PECOS PAC ID: 5294700381 Enrollment ID: I20040901000302 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Alison C Romstad |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1275502841 PECOS PAC ID: 8426017674 Enrollment ID: I20041005000385 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Lois R Sipprell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1760491005 PECOS PAC ID: 0840249074 Enrollment ID: I20050114000361 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Melissa K Sorenson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1871643825 PECOS PAC ID: 2163461609 Enrollment ID: I20050426000023 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Debra L Burgy |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1679533806 PECOS PAC ID: 1052353729 Enrollment ID: I20050524000572 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Jennifer L Welsh |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1215045885 PECOS PAC ID: 8022036656 Enrollment ID: I20051102000854 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Susan Grace Rossi |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1285734376 PECOS PAC ID: 3870598766 Enrollment ID: I20060928000023 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Scott J Fairbairn |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1174553747 PECOS PAC ID: 1951302975 Enrollment ID: I20070118000106 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Steven F Lawler |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1770546269 PECOS PAC ID: 2961500269 Enrollment ID: I20070611000384 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Marcia A Hoffman |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700869278 PECOS PAC ID: 0840376463 Enrollment ID: I20080324000530 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Anil Kumar |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1740340611 PECOS PAC ID: 1951393982 Enrollment ID: I20080325000410 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Elizabeth A Toth |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053580563 PECOS PAC ID: 3173602745 Enrollment ID: I20080507000422 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Momodou Ceesay |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1649438417 PECOS PAC ID: 0648348102 Enrollment ID: I20081010000172 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Patricia C Henjum |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1700807021 PECOS PAC ID: 2466514724 Enrollment ID: I20081219000421 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Frederick S Mosch |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1154403764 PECOS PAC ID: 1153470620 Enrollment ID: I20090513000248 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Sandra J Turbes |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1659364099 PECOS PAC ID: 2365496932 Enrollment ID: I20091029000275 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Douglas J Watkins |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1992795652 PECOS PAC ID: 6002956331 Enrollment ID: I20091217000634 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Angela K Farrington |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568498913 PECOS PAC ID: 3173664703 Enrollment ID: I20100105000413 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Cynthia A Carlson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1427035401 PECOS PAC ID: 9931242997 Enrollment ID: I20100130000128 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Robert J Helgren |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1336177971 PECOS PAC ID: 2668516618 Enrollment ID: I20100215000643 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Mary B Carlson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1144284274 PECOS PAC ID: 0143356469 Enrollment ID: I20100325000942 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Barry Larson |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1275518631 PECOS PAC ID: 1052223708 Enrollment ID: I20100420000893 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Bradley Allen Langley |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1083604722 PECOS PAC ID: 2668500877 Enrollment ID: I20100510000252 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | William J Hamilton |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1194715748 PECOS PAC ID: 4688702806 Enrollment ID: I20100510000372 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Kelsi K Nelson |
---|---|
Provider Type | Practitioner - Family Practice |
Provider Identifiers | NPI Number: 1992733976 PECOS PAC ID: 3375528151 Enrollment ID: I20100603000767 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Renee K Doering |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1023044484 PECOS PAC ID: 6103018254 Enrollment ID: I20101007000302 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Ruby L Schoen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1932417581 PECOS PAC ID: 2062601347 Enrollment ID: I20110118001262 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Ngum Ngwa |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1245537869 PECOS PAC ID: 6002092939 Enrollment ID: I20110510000890 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Melanie D Ashfeld |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1669769022 PECOS PAC ID: 0042480006 Enrollment ID: I20110830000424 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Kelli A Petersen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1164702742 PECOS PAC ID: 9739354549 Enrollment ID: I20111206000627 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Jane C Pederson |
---|---|
Provider Type | Practitioner - Geriatric Medicine |
Provider Identifiers | NPI Number: 1508147224 PECOS PAC ID: 3678588696 Enrollment ID: I20111230000484 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Judy L Palmer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1013284975 PECOS PAC ID: 5496912354 Enrollment ID: I20120203000347 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Joan Sang Luknic |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1780959551 PECOS PAC ID: 6406019256 Enrollment ID: I20120515000515 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Joy C Laansma |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1659623999 PECOS PAC ID: 4486807070 Enrollment ID: I20130109000789 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Rita A Anderson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1609217769 PECOS PAC ID: 6103050224 Enrollment ID: I20131003000305 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Debra L Stassen |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1518399294 PECOS PAC ID: 0840424719 Enrollment ID: I20131008001050 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Stacie L Straus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1184169542 PECOS PAC ID: 6002198041 Enrollment ID: I20170126001388 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Michaela M Cielinski |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1801320312 PECOS PAC ID: 5890072698 Enrollment ID: I20170504000546 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Natalie R Cowell |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1003351602 PECOS PAC ID: 2163791302 Enrollment ID: I20170703001880 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Amy Kammerer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1043746761 PECOS PAC ID: 7719251594 Enrollment ID: I20170918000872 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Jamie Inhoff |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1407357122 PECOS PAC ID: 4385907146 Enrollment ID: I20180410001563 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | John O Nyaenya |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1710470075 PECOS PAC ID: 6800144924 Enrollment ID: I20180807001501 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Abigail C Hartin |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1215415997 PECOS PAC ID: 9638417066 Enrollment ID: I20190211001870 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Samantha J Giffrow |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508339326 PECOS PAC ID: 8224378344 Enrollment ID: I20190327000654 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Brandi Reilly |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1568929115 PECOS PAC ID: 4082955851 Enrollment ID: I20190403002126 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Christina Kern |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1487113403 PECOS PAC ID: 0143563114 Enrollment ID: I20190514001606 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Marianne Loftus |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1972153443 PECOS PAC ID: 0446681902 Enrollment ID: I20200518000061 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Christina Bricout |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508485970 PECOS PAC ID: 6103247812 Enrollment ID: I20200605000151 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Jennifer Voss |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1033746714 PECOS PAC ID: 1153742770 Enrollment ID: I20200605000822 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Kelli Lynn Bronder |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1053073866 PECOS PAC ID: 4587045570 Enrollment ID: I20220721003893 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Elizabeth Margaret Fairbairn |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1982269684 PECOS PAC ID: 5496082562 Enrollment ID: I20220726003486 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Alissa Marie Abraham |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1396417572 PECOS PAC ID: 5193110450 Enrollment ID: I20221111001468 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Christina Ruth Krambeer |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1326745811 PECOS PAC ID: 0648645937 Enrollment ID: I20230419002225 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Michelle Ann Killam |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1295428019 PECOS PAC ID: 4981063005 Enrollment ID: I20230707002478 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Ashley Kumar |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1922725605 PECOS PAC ID: 6901278126 Enrollment ID: I20230720002975 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Paris Strom |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1508642737 PECOS PAC ID: 9537502166 Enrollment ID: I20240209002959 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Provider Name | Eva Dominie Wilson |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1063084127 PECOS PAC ID: 4385089911 Enrollment ID: I20240305001525 |
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
News Archive
When researchers discovered the primary genetic defect that causes cystic fibrosis (CF) back in 1989, they opened up a new realm of research into treatment and a cure for the disease. Since then, scientists have been able to clone the defective gene and study its effects in animals. Now researchers at the University of North Carolina at Chapel Hill have developed a technique for observing the defects at work in human tissue donated by patients with CF.
"The Obama administration's new Global Health Initiative, designed to broaden and better integrate health programming overseas, deserves wide support. But stalling on global AIDS threatens to undermine the worthy goals of the initiative," Chris Collins, vice president and director of public polity for the Foundation for AIDS Research, writes in a Boston Globe letter to the editor calling for sustained support for PEPFAR.
The Visiting Nurse Service of New York (VNSNY) Center for Home Health Care Policy & Research, the only research center focused on studying home health care in the U.S., has received funding from The Center for Technology and Aging to test state-of-the art information technology (IT) strategies designed to help elderly patients with cognitive impairment and their caregivers safely manage multiple medications.
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.
› Verified 3 days ago
Morningstar Wellness Center, Ltd Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 800 Washington Ave N, Suite 202, Minneapolis, MN 55401 Phone: 612-455-2920 Fax: 612-455-2921 | |
Healthpartners Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 8170 33rd Ave S, Ms 21110q, Minneapolis, MN 55425 Phone: 952-883-7469 Fax: 952-883-5395 | |
Boynton Health Service Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 410 Church St Se, Minneapolis, MN 55455 Phone: 612-625-8400 Fax: 612-625-1434 | |
Corban Health Care, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5141 36th Ave S, Minneapolis, MN 55417 Phone: 612-644-9047 | |
Fairview Express Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2025 E River Pkwy, Minneapolis, MN 55414 Phone: 612-301-0115 | |
Evernorth Care Providers - Delaware Pa Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 121 Washington Ave N Fl 2, Minneapolis, MN 55401 Phone: 773-292-4800 Fax: 312-564-4059 | |
Allina Health Home Hospital Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2925 Chicago Ave, Minneapolis, MN 55407 Phone: 612-262-7800 |